Neuren Pharmaceuticals Ltd
ASX:NEU
Intrinsic Value
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. [ Read More ]
The intrinsic value of one
NEU
stock under the Base Case scenario is
18.68
AUD.
Compared to the current market price of 20.25 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 8%.
Neuren Pharmaceuticals Ltd's market capitalization is 2.6B AUD.
NEU stock price is 20.25 AUD.
NEU stock (18.68 AUD) is 8% less than its price (20.25 AUD).
NEU stock (6.66 AUD) is 67% less than its price (20.25 AUD). Open Relative Valuation
NEU has upside potential of 35% compared to the average analyst price target.
Open Wall St Estimates
NEU's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
NEU has a very low three-year average ROE (Return on Equity): 3%. The company is not efficient at transforming stockholders' equity into net income.
NEU's Revenue has grown by an exceptional 1 403% over the past 12 months.
NEU's ROE (Return on Equity) has significantly increased in the last 3 years from -48% to 127%.
NEU's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -115 493% to 1 732%.
NEU has positive Operating Income for the last twelve months.
NEU has positive Net Income for the last twelve months.
NEU's ROE (Return on Equity) for the past 12 months is very high and is equal to 127%.
NEU's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 1 732%.
NEU has positive Free Cash Flow for the last twelve months.
NEU's Revenue has been growing by an exceptional 550% per year for the last 3 years.
NEU has negative three-year average ROIC (Return on Invested Capital): -16 262%. The company is not efficient at using invested capital to generate operating income.
NEU's short-term assets (247m AUD) exceed its short-term liabilties (43m AUD).
NEU's long-term assets (248m AUD) exceed its long-term liabilties (43m AUD).
NEU's D/E (Debt to Equity) is very low and is equal to 0.
NEU's Altman Z-Score is very high and is equal to 48.4.
Valuation Backtest
Neuren Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
NEU
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Neuren Pharmaceuticals Ltd
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
| Current Assets | 247.2m |
| Cash & Short-Term Investments | 228.5m |
| Receivables | 18.6m |
| Non-Current Assets | 814k |
| PP&E | 43k |
| Other Non-Current Assets | 771k |
| Current Liabilities | 42.8m |
| Accounts Payable | 3.4m |
| Other Current Liabilities | 39.3m |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
|
Revenue
|
237.6m
AUD
|
|
Operating Expenses
|
-32.7m
AUD
|
|
Operating Income
|
204.9m
AUD
|
|
Other Expenses
|
-47.9m
AUD
|
|
Net Income
|
157.1m
AUD
|
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
NEU Profitability Score
Profitability Due Diligence
Neuren Pharmaceuticals Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Neuren Pharmaceuticals Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
NEU Solvency Score
Solvency Due Diligence
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
NEU
is 27.27 AUD
with a low forecast of 23.03 AUD and a high forecast of 32.55 AUD.
Shareholder Return
NEU Price
Neuren Pharmaceuticals Ltd
| Average Annual Return | 99.87% |
| Standard Deviation of Annual Returns | 105.57% |
| Max Drawdown | -68% |
| Market Capitalization | 2.6B AUD |
| Shares Outstanding | 131 085 700 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Neuren Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The firm has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. The company is also planning a Phase II trial in Prader-Willi syndrome.
Contact
IPO
Employees
Officers
The intrinsic value of one
NEU
stock under the Base Case scenario is
18.68
AUD.
Compared to the current market price of 20.25 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 8%.
You don't have any saved screeners yet
